Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that SLS-002 (intranasal racemic ketamine) has been selected for inclusion in an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial is funded by the U.S. Department of Defense's (DOD) Defense Health Agency and led by the Warfighter Readiness, Performance, and Brain Health Project Management Office, part of the U.S. Army Medical Materiel Development Activity.
- "We would like to thank the project managers and subcontractors to this study for their tireless effort in moving this program forward.
- In addition, the trial will evaluate several biomarkers associated with PTSD and assessments of treatment safety and tolerability.
- "This study provides an ideal opportunity to study SLS-002 for PTSD," said Tim Whitaker, M.D., Chief Medical Officer of Seelos.
- "The current approved pharmacologic treatments for PTSD have a number of limitations, and there remains a high unmet medical need.